Cargando…
Patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sFasL concentrations
BACKGROUND: Fas ligand (FasL) is one ligand that activates extrinsic apoptosis pathway. High expression in lymphocytes of FasL have been found in patients with acute rejection of liver transplantation (LT). No high blood concentrations of soluble FasL (sFasL) have been found in patients with acute L...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037289/ https://www.ncbi.nlm.nih.gov/pubmed/36970008 http://dx.doi.org/10.12998/wjcc.v11.i8.1753 |
_version_ | 1784911845885214720 |
---|---|
author | Lorente, Leonardo Rodriguez, Sergio T Sanz, Pablo González-Rivero, Agustín F Pérez-Cejas, Antonia Padilla, Javier Díaz, Dácil González, Antonio Martín, María M Jiménez, Alejandro Cerro, Purificación Portero, Julián Barrera, Manuel A |
author_facet | Lorente, Leonardo Rodriguez, Sergio T Sanz, Pablo González-Rivero, Agustín F Pérez-Cejas, Antonia Padilla, Javier Díaz, Dácil González, Antonio Martín, María M Jiménez, Alejandro Cerro, Purificación Portero, Julián Barrera, Manuel A |
author_sort | Lorente, Leonardo |
collection | PubMed |
description | BACKGROUND: Fas ligand (FasL) is one ligand that activates extrinsic apoptosis pathway. High expression in lymphocytes of FasL have been found in patients with acute rejection of liver transplantation (LT). No high blood concentrations of soluble FasL (sFasL) have been found in patients with acute LT rejection; however, the samples size of those studies was small. AIM: To determine whether patients with hepatocellular carcinoma (HCC) that dead during the first year of LT have higher blood sFasL concentrations previously to LT that those who that remain alive in a study of higher sample size. METHODS: Patients underwent LT due to HCC were included in this retrospective study. Serum sFasL levels prior to LT were measured and one-year LT mortality was registered. RESULTS: Non-surviving patients (n = 14) showed higher serum sFasL levels [477 (269-496) vs 85 (44-382) pg/mL; P < 0.001] than surviving patients (n = 113). Serum sFasL levels (pg/mL) were associated with mortality (OR = 1.006; 95%CI = 1.003-1.010; P = 0.001) independently of age of LT donor in the logistic regression analysis. CONCLUSION: We report for the first time that HCC patients who die within the first year of HT have higher blood sFasL concentrations prior to HT than those who remain alive. |
format | Online Article Text |
id | pubmed-10037289 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-100372892023-03-25 Patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sFasL concentrations Lorente, Leonardo Rodriguez, Sergio T Sanz, Pablo González-Rivero, Agustín F Pérez-Cejas, Antonia Padilla, Javier Díaz, Dácil González, Antonio Martín, María M Jiménez, Alejandro Cerro, Purificación Portero, Julián Barrera, Manuel A World J Clin Cases Retrospective Study BACKGROUND: Fas ligand (FasL) is one ligand that activates extrinsic apoptosis pathway. High expression in lymphocytes of FasL have been found in patients with acute rejection of liver transplantation (LT). No high blood concentrations of soluble FasL (sFasL) have been found in patients with acute LT rejection; however, the samples size of those studies was small. AIM: To determine whether patients with hepatocellular carcinoma (HCC) that dead during the first year of LT have higher blood sFasL concentrations previously to LT that those who that remain alive in a study of higher sample size. METHODS: Patients underwent LT due to HCC were included in this retrospective study. Serum sFasL levels prior to LT were measured and one-year LT mortality was registered. RESULTS: Non-surviving patients (n = 14) showed higher serum sFasL levels [477 (269-496) vs 85 (44-382) pg/mL; P < 0.001] than surviving patients (n = 113). Serum sFasL levels (pg/mL) were associated with mortality (OR = 1.006; 95%CI = 1.003-1.010; P = 0.001) independently of age of LT donor in the logistic regression analysis. CONCLUSION: We report for the first time that HCC patients who die within the first year of HT have higher blood sFasL concentrations prior to HT than those who remain alive. Baishideng Publishing Group Inc 2023-03-16 2023-03-16 /pmc/articles/PMC10037289/ /pubmed/36970008 http://dx.doi.org/10.12998/wjcc.v11.i8.1753 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Retrospective Study Lorente, Leonardo Rodriguez, Sergio T Sanz, Pablo González-Rivero, Agustín F Pérez-Cejas, Antonia Padilla, Javier Díaz, Dácil González, Antonio Martín, María M Jiménez, Alejandro Cerro, Purificación Portero, Julián Barrera, Manuel A Patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sFasL concentrations |
title | Patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sFasL concentrations |
title_full | Patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sFasL concentrations |
title_fullStr | Patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sFasL concentrations |
title_full_unstemmed | Patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sFasL concentrations |
title_short | Patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sFasL concentrations |
title_sort | patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sfasl concentrations |
topic | Retrospective Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037289/ https://www.ncbi.nlm.nih.gov/pubmed/36970008 http://dx.doi.org/10.12998/wjcc.v11.i8.1753 |
work_keys_str_mv | AT lorenteleonardo patientswithhepatocellularcarcinomathatdieduringthefirstyearoflivertransplantationhavehighbloodsfaslconcentrations AT rodriguezsergiot patientswithhepatocellularcarcinomathatdieduringthefirstyearoflivertransplantationhavehighbloodsfaslconcentrations AT sanzpablo patientswithhepatocellularcarcinomathatdieduringthefirstyearoflivertransplantationhavehighbloodsfaslconcentrations AT gonzalezriveroagustinf patientswithhepatocellularcarcinomathatdieduringthefirstyearoflivertransplantationhavehighbloodsfaslconcentrations AT perezcejasantonia patientswithhepatocellularcarcinomathatdieduringthefirstyearoflivertransplantationhavehighbloodsfaslconcentrations AT padillajavier patientswithhepatocellularcarcinomathatdieduringthefirstyearoflivertransplantationhavehighbloodsfaslconcentrations AT diazdacil patientswithhepatocellularcarcinomathatdieduringthefirstyearoflivertransplantationhavehighbloodsfaslconcentrations AT gonzalezantonio patientswithhepatocellularcarcinomathatdieduringthefirstyearoflivertransplantationhavehighbloodsfaslconcentrations AT martinmariam patientswithhepatocellularcarcinomathatdieduringthefirstyearoflivertransplantationhavehighbloodsfaslconcentrations AT jimenezalejandro patientswithhepatocellularcarcinomathatdieduringthefirstyearoflivertransplantationhavehighbloodsfaslconcentrations AT cerropurificacion patientswithhepatocellularcarcinomathatdieduringthefirstyearoflivertransplantationhavehighbloodsfaslconcentrations AT porterojulian patientswithhepatocellularcarcinomathatdieduringthefirstyearoflivertransplantationhavehighbloodsfaslconcentrations AT barreramanuela patientswithhepatocellularcarcinomathatdieduringthefirstyearoflivertransplantationhavehighbloodsfaslconcentrations |